Clincosm LogoSign in Get a demo

Genetic Evaluation of Renal Cell Carcinoma; Predicting Biomarkers for Renal Cell Carcinoma

Sponsor
Zealand University Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT03414827
Collaborator
(none)
120
Enrollment
1
Location
46
Anticipated Duration (Months)
2.6
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Recruitment of participants to the study takes place at the urological department at Zealand University Hospital, Roskilde, Feb. 2018-April 2018. 10 people with diagnosis of renal cancer should be recruited in phases 1. Subsequently, biological materials from 100 patients with kidney cancer will be used from the national Biobank. In phase 3, 10 patients will be recruited for the final gene test.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    120 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Genetic Evaluation of Renal Cell Carcinoma; Predicting Biomarkers for Renal Cell Carcinoma
    Actual Study Start Date :
    Feb 1, 2019
    Anticipated Primary Completion Date :
    Dec 1, 2022
    Anticipated Study Completion Date :
    Dec 1, 2022

    Outcome Measures

    Primary Outcome Measures

    1. DNA [30 days]

      Sequence variation in specific genes

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients who have been diagnosed with kidney cancer.
    Exclusion Criteria:

    • Patients without signs of malignancy at final histology report.

    • Incapacitated patients.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Zealand University Hospital Roskilde Denmark 4000

    Sponsors and Collaborators

    • Zealand University Hospital

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Nessn Azawi, Clinical Professor, Zealand University Hospital
    ClinicalTrials.gov Identifier:
    NCT03414827
    Other Study ID Numbers:
    • SJ-608
    First Posted:
    Jan 30, 2018
    Last Update Posted:
    Sep 20, 2021
    Last Verified:
    Sep 1, 2021
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Carcinoma
    Carcinoma, Renal Cell
    Kidney Neoplasms

    Study Results

    No Results Posted as of Sep 20, 2021